Avinger Receives CE Marking Approval for Next Generation Pantheris Image-Guided Atherectomy Device
20. Dezember 2017 08:30 ET
|
Avinger, Inc.
REDWOOD CITY, Calif., Dec. 20, 2017 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced Conformité...
Avinger Secures Waiver and Consent to CRG Loan Agreement
14. Dezember 2017 16:01 ET
|
Avinger, Inc.
REDWOOD CITY, Calif., Dec. 14, 2017 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:AVGR), a developer and manufacturer of image-guided, catheter-based systems for the treatment of peripheral arterial...
Avinger Announces Change in Board Leadership
11. Dezember 2017 16:15 ET
|
Avinger, Inc.
REDWOOD CITY, Calif., Dec. 11, 2017 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:AVGR) (“Avinger” or the “Company”), a leading developer of innovative treatments for peripheral artery disease (PAD),...
Avinger Announces Third Quarter 2017 Results
09. November 2017 16:01 ET
|
Avinger, Inc.
REDWOOD CITY, Calif., Nov. 09, 2017 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:AVGR) (“Avinger” or the “Company”), a leading developer of innovative treatments for peripheral artery disease (PAD),...
Avinger Enters into Common Stock Purchase Agreement for up to $15.0 Million with Lincoln Park Capital
06. November 2017 07:30 ET
|
Avinger, Inc.
REDWOOD CITY, Calif., Nov. 06, 2017 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:AVGR) (the “Company”), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced...
Avinger Receives 510(k) Clearance for Design Modifications to Enhance Performance of Pantheris Image-Guided Atherectomy Device
31. Oktober 2017 16:01 ET
|
Avinger, Inc.
REDWOOD CITY, Calif., Oct. 31, 2017 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:AVGR), a leading developer of innovative treatments for Peripheral Artery Disease (PAD), today announced that the...
Avinger to Announce Third Quarter 2017 Results on November 9, 2017
31. Oktober 2017 08:00 ET
|
Avinger, Inc.
REDWOOD CITY, Calif., Oct. 31, 2017 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced that it will...
Avinger Announces First Patient Enrolled in its IDE Study of the Pantheris Image-Guided Atherectomy System for Treatment of In-Stent Restenosis
19. Oktober 2017 16:01 ET
|
Avinger, Inc.
REDWOOD CITY, Calif., Oct. 19, 2017 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:AVGR), a leading developer of innovative treatments for Peripheral Artery Disease (PAD), today announced initiation of...
Avinger Receives CE Marking Approval for In-Stent Restenosis Treatment Indication With Pantheris Image-Guided Atherectomy
26. September 2017 16:01 ET
|
Avinger Inc
REDWOOD CITY, Calif., Sept. 26, 2017 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:AVGR), a leading developer of innovative treatments for Peripheral Artery Disease (PAD), today announced Conformité...
Avinger Announces Second Quarter 2017 Results
08. August 2017 16:01 ET
|
Avinger Inc
REDWOOD CITY, Calif., Aug. 08, 2017 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:AVGR) (the “Company”), a leading developer of innovative treatments for peripheral artery disease (PAD), today reported...